Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab for MRD in LBCL
NCT06670105Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2025
- Primary completion
- Jan 2030
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Rate of undetectable Minimal Residual Disease (MRD). Planned start Jun 2025; status: withdrawn.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06670105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06670105.